Arrivent Biopharma company information, Employees & Contact Information

Mintz Advises ArriVent BioPharma on $75 Million Underwritten Public Offering Mintz

ArriVent goes Further into PACC mutations | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ArriVent BioPharma expects to raise $75M from stock sale The Business Journals

ArriVent Appoints Brent Rice as Chief Commercial Officer citybiz

ArriVent BioPharma stock steady as Oppenheimer reiterates Outperform rating Investing.com

Frontline Firmonertinib Generates Durable Efficacy in EGFR PACC–Mutant NSCLC OncLive

$75M Stock Offering: How ArriVent BioPharma Plans to Accelerate Cancer Drug Development Stock Titan

ArriVent continues to bulk out ADC pipeline, paying Lepu $47M for preclinical GI asset Fierce Biotech

Cancer Biotech ArriVent Lands an ADC for GI Malignancies and Makes Best-in-Class Claim MedCity News

ArriVent inks $47 Mn cancer drug deal with Lepu Biopharma ET Pharma

ArriVent Biopharma Launches with Up To $150M in Series A GlobeNewswire

Aarvik Therapeutics and ArriVent Biopharma Announce Research Collaboration to Advance Novel Oncology Drug Candidate Using Aarvik’s Proprietary Modular Antibody Platform Business Wire

AVBP Stock Price and Chart — NASDAQ:AVBP TradingView

ArriVent’s $175M Upsized IPO Builds Momentum on Heels of CG Oncology Offering BioSpace

ArriVent Appoints Chris Nolet to its Board of Directors citybiz

Allist and ArriVent Announce Interim Results from Ongoing GlobeNewswire

Black Diamond joins ArriVent in the PACC pack | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Mintz Advises on ArriVent BioPharma’s Upsized IPO on the Nasdaq Global Market Mintz

Mintz Advises ArriVent Biopharma in $155M Series B Financing Mintz

InnoCare and ArriVent Announce Clinical Development Collaboration GlobeNewswire

ArriVent bulks out ADC portfolio via $615M Alphamab deal FirstWord Pharma

ArriVent BioPharma stock maintains Buy rating at H.C. Wainwright Investing.com

Metagenomi, Arrivent to sneak through crack in IPO window Fierce Biotech

AVBP IPO News - Cancer biotech ArriVent BioPharma sets terms for $150 million IPO renaissancecapital.com

ArriVent BioPharma stock maintains Buy rating at H.C. Wainwright on strong NSCLC trial data Investing.com

StockWatch: IPO Revival? CG Oncology, ArriVent Raise a Combined $555M Genetic Engineering and Biotechnology News

ArriVent raises $150M to bring Chinese drugs to Western markets Fierce Biotech

FDA Grants Breakthrough Therapy Designation to Furmonertinib for EGFR Exon 20 Insertion+ NSCLC OncLive

After a $3B exit, a biopharma veteran unveils a new company and a global focus MedCity News

ArriVent wows investors with promising China-developed lung cancer treatment thebambooworks.com

ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants The Manila Times

Elles Arrivent Le Tour de France Femmes